(i) Understanding disease through extracellular vesicles (EVs) and translating this knowledge for developing new class of precision therapeutics, (ii) Develop EVs as programmable carriers of nucleic acid-based drugs including siRNA, antisense oligonucleotides and CRISPR system, for the delivery of treatments to specific cells and tissues.